Overview

• The Suite Ride experiment on Axiom Mission-4 tested consumer continuous glucose monitors and insulin pens aboard the International Space Station.
• Early findings indicate CGMs produced readings comparable to Earth-based measurements and relayed data to the ground during the 18-day flight.
• Researchers reported firsts on the station, including the first continuous glucose monitoring of crew, the first insulin pens flown, and validation across multiple measurement methods.
• Insulin pens have returned for post‑flight laboratory analysis to assess formulation integrity before considering operational use.
• Burjeel Holdings and Axiom Space announced the preliminary results in New York on September 26 and highlighted potential applications for remote healthcare in hard-to-reach environments.